Taking into consideration that the level of natural NE inhibitors remains diminished and NE activity is elevated in cardiovascular and pulmonary diseases, such as ARDS, COPD, and acute lung injuries, engineered NE inhibitors are tested for potential treatment options (von Nussbaum et al., 2015; Polverino et al., 2017). The gene discussed is ELANE; the disease is lung disorder.